



Science Industry Australia



in Biotechnology and Life Sciences

The Fluorescence Applications in Biotechnology and Life Sciences Network
and

Science Industry Australia Association
invite you to a seminar on

“Using Proteomics to Investigate Medical Questions”

Professor Mark Baker, *Facility Director, Australian Proteome Analysis Facility*
and

“Investing in a Cooperative Research Centre”

Mr Tony Hill, *MD, Capital Consulting Pty Ltd*

Thursday 6th December 2007, 3.00 – 5.00pm

WHERE: Leica Microsystems Pty Ltd, Unit 3, 112-118 Talavera Rd, North Ryde

Australian Proteome Analysis Facility

Proteomics is leading the way in addressing healthcare issues and discovering new drugs. It is the study of proteins found in humans, plants, animals, and microbes, and the expression of particular proteins can be used as “biomarkers” of health, disease and/or quality.

APAF is Australia’s premier proteomics institution. APAF Ltd was the birthplace of the term proteomics in 1995 and the first high throughput lab worldwide. APAF research and development has continued in all areas of technology development and industry, providing world leading advances and services for over a decade.

APAF is a developer of new technologies for protein discovery. APAF core competencies include

- 2 Dimensional Electrophoresis
- Mass Spectrometry and Liquid Chromatography
- Protein Chemistry and Protein Arrays
- Multiplexing assays
- Biomarker Discovery
- High-throughput cell based screening assays
- Therapeutic recombinant protein expression and purification

Mark Baker

Mark is a Director of APAF and Professor of Proteomics, Macquarie University. Mark received his PhD in 1985 from Macquarie University and undertook postdoctoral studies at Monash University, John Curtin School of Medical Research

and Howard Hughes Medical Research Institute University of Michigan.

Mark’s previous industry experience is in the development of new biochip platforms (through LumiCyte, USA). He was the founder of the Gynaecological Cancer Research Centre, Royal Women’s Hospital, Melbourne, is and Secretary of the Australasian Proteomics Society. Mark is currently a member of the Science Industry Action Agenda Leader’s Group. He won the 1994 Sports Medicine Australia Order of Fellows, the 1991 Howard Florey Young Investigator Medal.

Mark’s interests are in biomarker discovery, proteomic technologies, research commercialisation, building the Australian biotech sector. He holds grants with proteomics industry leaders including GE Healthcare, QIAGEN, Applied Biosystems and has most recently developed novel immunodepletion strategies using chicken eggs.

Cooperative Research Centre

As an example of potential investment in a \$100 million CRC to be established in 2008 and which is tentatively named CRC for Advanced Cell Technologies. It will focus on the development of precision instrumentation, reagents and software to expand the boundaries in diagnostics, and the treatment of disease by specialising in:

- Real time multiplex detection of pathogens in a health care setting developing approaches for rapid detection of a range of harmful microorganisms

- Purification of cell populations developing approaches for efficient purification of important cell populations such as adult stem cells
- Cellular Biosensors developing novel cellular assays based on the use of genetically encoded fluorescent probes.

Companies are invited to nominate research priorities. Twenty leading researchers from 6 Australian universities and 2 government departments are cooperating.

Tony Hill

Tony Hill established Capital Hill Consulting Pty Ltd in 1999 to provide high-level advice on large-scale research funding, strategic research management and challenging collaboration issues. He was formerly Manager of the Cooperative Research Centres (CRC) Program in the Department of Industry, Science and Resources. Capital Hill Consulting is located in Canberra and continues to maintain a close relationship to national policy and processes.

Tony has assisted more than 30 CRC applicants in their application process. In the 2000, 2002, 2004 and 2006 selection rounds, he provided support and

advice to applications that attracted more than \$465 million worth of CRC grants over seven years. Tony's experience includes the establishment of a mutual working partnership between all the stakeholders in research, industry and government.

FABLS

The ARC Network for **Fluorescence Applications in Biotechnology and Life Sciences** (FABLS) inspires and coordinates research programs relating to applications of fluorescence that require a high degree of interaction between biology, physics, chemistry, bioengineering and medicine. The FABLS network includes over 365 researchers and industry representatives from Australia and around the world.

SIA

Science Industry Australia is the national industry association which represents the professional science industry, and our members include scientific and life science product and equipment suppliers; scientific, analytical and diagnostic equipment manufacturers, exporters and importers; chemical and gas companies; software companies and specialised recruiters.

This is a free event

RSVP to David Tayler, FABLS Ph :9850 9078, Email: dtayler@ics.mq.edu.au

By 30 November 2007